Evaluation of the prevention, treatment and synergistic activity between Helicobacter pylori IgY antibodies and pantaprazole on AGS cell line and C57BL/6 Mice
-
Sara Kamal Shahsavar
,
Zahra Esmaeili
,
Hamid Ariannejad
,
Mohammadreza Nassiri
,
Ali Beheshti Namdar
,
Amir Hossein Jafarian
,
Ramin Sadeghi
,
Vahid Reza Dabbagh
,
Kiarash Ghazvini
Abstract
Background and Objectives: The growing resistance of Helicobacter pylori to antibiotics poses significant challenges in managing gastric ulcers. The application of IgY antibodies against H. pylori is a promising strategy. The current study evaluated the preventive and synergistic effects of IgY antibodies in conjunction with pantoprazole for treating H. pylori infection.
Materials and Methods: This investigation specifically focused on the inhibitory effects of IgY in the AGS cell line infected with H. pylori. In addition, the synergistic activity of IgY with pantoprazole and its preventive and therapeutic effects were assessed in male C57BL/6 mice.
Results: The findings indicated that IgY antibodies possess a substantial inhibitory effect on the adhesion of H. pylori to the AGS cell line. Furthermore, IgY antibodies resulted in a significant reduction (P<0.05) in the population of H. pylori and the severity of gastritis in infected C57BL/6 mice in both treatment and prevention groups. Notably, the optimal outcome was observed when IgY was administered alongside pantoprazole.
Conclusion: The use of IgY has the potential to repair damaged cells and prevent infection by decreasing bacterial adherence to gastric epithelial cells. Given its synergistic effect with pantoprazole, IgY can be recommended as a suitable complementary treatment in conjunction with pantoprazole.
1. Wang B, Yang J, Cao S, Wang H, Pan X, Zhu J, et al. Preparation of specific anti-Helicobacter pylori yolk antibodies and their antibacterial effects. Int J Clin Exp Pathol 2014; 7: 6430-6437.
2. Suarez G, Reyes VE, Beswick EJ. Immune response to H. pylori. World J Gastroenterol 2006; 12: 5593-5598.
3. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology 2018; 155: 1372-1382. e17.
4. Ansari S, Yamaoka Y. Helicobacter pylori virulence factors exploiting gastric colonization and its pathogenicity. Toxins (Basel) 2019; 11: 677.
5. Ghasemi-Kebria F, Ghaemi E, Azadfar S, Roshandel G. Epidemiology of Helicobacter pylori infection among Iranian children. Arab J Gastroenterol 2013; 14: 169-172.
6. Eshraghian A. Epidemiology of Helicobacter pylori infection among the healthy population in Iran and countries of the Eastern Mediterranean Region: a systematic review of prevalence and risk factors. World J Gastroenterol 2014; 20: 17618-17625.
7. Ansari S, Yamaoka Y. Helicobacter pylori infection, its laboratory diagnosis, and antimicrobial resistance: a perspective of clinical relevance. Clin Microbiol Rev 2022; 35(3): e0025821.
8. Wang Z, Han W, Xue F, Zhao Y, Wu P, Chen Y, et al. Nationwide gastric cancer prevention in China, 2021-2035: a decision analysis on effect, affordability and cost-effectiveness optimisation. Gut 2022; 71: 2391-2400.
9. Yousefi-Avarvand A, Vaez H, Tafaghodi M, Sahebkar AH, Arzanlou M, Khademi F. Antibiotic resistance of Helicobacter pylori in Iranian children: a systematic review and meta-analysis. Microb Drug Resist 2018; 24: 980-986.
10. Khademi F, Sahebkar A. An updated systematic review and meta-analysis on the Helicobacter pylori antibiotic resistance in Iran (2010–2020). Microb Drug Resist 2020; 26: 1186-1194.
11. Khademi F, Sahebkar AH, Vaez H, Arzanlou M, Peeridogaheh H. Characterization of clarithromycin-resistant Helicobacter pylori strains in Iran: A systematic review and meta-analysis. J Glob Antimicrob Resist 2017; 10: 171-178.
12. Nomura S, Suzuki H, Masaoka T, Kurabayashi K, Ishii H, Kitajima M, et al. Effect of dietary anti‐urease immunoglobulin Y on Helicobacter pylori infection in Mongolian gerbils. Helicobacter 2005; 10: 43-52.
13. Pereira EPV, Van Tilburg MF, Florean EOPT, Guedes MIF. Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review. Int Immunopharmacol 2019; 73: 293-303.
14. Borhani K, Mobarez AM, Khabiri AR, Behmanesh M, Khoramabadi N. Production of specific IgY Helicobacter pylori recombinant OipA protein and assessment of its inhibitory effects towards attachment of H. pylori to AGS cell line. Clin Exp Vaccine Res 2015; 4: 177-183.
15. Suzuki H, Nomura S, Masaoka T, Goshima H, Kamata N, Kodama Y, et al. Effect of dietary anti‐Helicobacter pylori‐urease immunoglobulin Y on Helicobacter pylori infection. Aliment Pharmacol Ther 2004; 20 Suppl 1: 185-192.
16. Cheng S, Li H, Luo J, Chi J, Zhao W, Lin J, et al. Egg yolk antibody combined with bismuth-based quadruple therapy in Helicobacter pylori infection rescue treatment: a single-center, randomized, controlled study. Front Microbiol 2023; 14: 1150129.
17. Borhani K, Mohabati Mobarez A, Khabiri AR, Behmanesh M, Khoramabadi N. Inhibitory effects of rHP-NAP IgY against Helicobacter pylori attachment to AGS cell line. Microb Pathog 2016; 97: 231-235.
18. Mony TJ, Kwon H-S, Won M-K, Kang YM, Lee S-H, Kim S-Y, et al. Anti-urease immunoglobulin (IgY) from egg yolk prevents Helicobacter pylori infection in a mouse model. Food Agric Immunol 2019; 30: 662-676.
19. Leiva CL, Gallardo MJ, Casanova N, Terzolo H, Chacana P. IgY-technology (egg yolk antibodies) in human medicine: A review of patents and clinical trials. Int Immunopharmacol 2020; 81: 106269.
20. Kovacs-Nolan J, Mine Y. Egg yolk antibodies for passive immunity. Annu Rev Food Sci Technol 2012; 3: 163-182.
21. Mine Y, Kovacs-Nolan J. Chicken egg yolk antibodies as therapeutics in enteric infectious disease: a review. J Med Food 2002; 5: 159-169.
22. Müller S, Schubert A, Zajac J, Dyck T, Oelkrug C. IgY antibodies in human nutrition for disease prevention. Nutr J 2015; 14: 109.
23. Do LH, Vi TT, Le HT, Do TM, Do DK, Nguyen DD, et al. The inhibitory effect of anti-urease IgY on Helicobacter pylori infection in Swiss albino mice. Pharm Sci Asia 2021; 48: 255-268.
24. Ayala G, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014; 20: 1450-1469.
25. Malekshahi ZV, Gargari SL, Rasooli I, Ebrahimizadeh W. Treatment of Helicobacter pylori infection in mice with oral administration of egg yolk-driven anti-UreC immunoglobulin. Microb Pathog 2011; 51: 366-372.
26. Shin JH, Yang M, Nam SW, Kim JT, Myung NH, Bang WG, et al. Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection. Clin Diagn Lab Immun 2002; 9: 1061-1066.
27. Shin J-H, Roe I-H, Kim H-G. Production of anti-Helicobacter pylori urease-specific immunoglobulin in egg yolk using an antigenic epitope of H. pylori urease. J Med Microbiol 2004; 53: 31-34.
28. Hong KS, Ki MR, Ullah HMA, Lee EJ, Kim YD, Chung MJ, et al. Preventive effect of anti-VacA egg yolk immunoglobulin (IgY) on Helicobacter pylori-infected mice. Vaccine 2018; 36: 371-380.
2. Suarez G, Reyes VE, Beswick EJ. Immune response to H. pylori. World J Gastroenterol 2006; 12: 5593-5598.
3. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology 2018; 155: 1372-1382. e17.
4. Ansari S, Yamaoka Y. Helicobacter pylori virulence factors exploiting gastric colonization and its pathogenicity. Toxins (Basel) 2019; 11: 677.
5. Ghasemi-Kebria F, Ghaemi E, Azadfar S, Roshandel G. Epidemiology of Helicobacter pylori infection among Iranian children. Arab J Gastroenterol 2013; 14: 169-172.
6. Eshraghian A. Epidemiology of Helicobacter pylori infection among the healthy population in Iran and countries of the Eastern Mediterranean Region: a systematic review of prevalence and risk factors. World J Gastroenterol 2014; 20: 17618-17625.
7. Ansari S, Yamaoka Y. Helicobacter pylori infection, its laboratory diagnosis, and antimicrobial resistance: a perspective of clinical relevance. Clin Microbiol Rev 2022; 35(3): e0025821.
8. Wang Z, Han W, Xue F, Zhao Y, Wu P, Chen Y, et al. Nationwide gastric cancer prevention in China, 2021-2035: a decision analysis on effect, affordability and cost-effectiveness optimisation. Gut 2022; 71: 2391-2400.
9. Yousefi-Avarvand A, Vaez H, Tafaghodi M, Sahebkar AH, Arzanlou M, Khademi F. Antibiotic resistance of Helicobacter pylori in Iranian children: a systematic review and meta-analysis. Microb Drug Resist 2018; 24: 980-986.
10. Khademi F, Sahebkar A. An updated systematic review and meta-analysis on the Helicobacter pylori antibiotic resistance in Iran (2010–2020). Microb Drug Resist 2020; 26: 1186-1194.
11. Khademi F, Sahebkar AH, Vaez H, Arzanlou M, Peeridogaheh H. Characterization of clarithromycin-resistant Helicobacter pylori strains in Iran: A systematic review and meta-analysis. J Glob Antimicrob Resist 2017; 10: 171-178.
12. Nomura S, Suzuki H, Masaoka T, Kurabayashi K, Ishii H, Kitajima M, et al. Effect of dietary anti‐urease immunoglobulin Y on Helicobacter pylori infection in Mongolian gerbils. Helicobacter 2005; 10: 43-52.
13. Pereira EPV, Van Tilburg MF, Florean EOPT, Guedes MIF. Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review. Int Immunopharmacol 2019; 73: 293-303.
14. Borhani K, Mobarez AM, Khabiri AR, Behmanesh M, Khoramabadi N. Production of specific IgY Helicobacter pylori recombinant OipA protein and assessment of its inhibitory effects towards attachment of H. pylori to AGS cell line. Clin Exp Vaccine Res 2015; 4: 177-183.
15. Suzuki H, Nomura S, Masaoka T, Goshima H, Kamata N, Kodama Y, et al. Effect of dietary anti‐Helicobacter pylori‐urease immunoglobulin Y on Helicobacter pylori infection. Aliment Pharmacol Ther 2004; 20 Suppl 1: 185-192.
16. Cheng S, Li H, Luo J, Chi J, Zhao W, Lin J, et al. Egg yolk antibody combined with bismuth-based quadruple therapy in Helicobacter pylori infection rescue treatment: a single-center, randomized, controlled study. Front Microbiol 2023; 14: 1150129.
17. Borhani K, Mohabati Mobarez A, Khabiri AR, Behmanesh M, Khoramabadi N. Inhibitory effects of rHP-NAP IgY against Helicobacter pylori attachment to AGS cell line. Microb Pathog 2016; 97: 231-235.
18. Mony TJ, Kwon H-S, Won M-K, Kang YM, Lee S-H, Kim S-Y, et al. Anti-urease immunoglobulin (IgY) from egg yolk prevents Helicobacter pylori infection in a mouse model. Food Agric Immunol 2019; 30: 662-676.
19. Leiva CL, Gallardo MJ, Casanova N, Terzolo H, Chacana P. IgY-technology (egg yolk antibodies) in human medicine: A review of patents and clinical trials. Int Immunopharmacol 2020; 81: 106269.
20. Kovacs-Nolan J, Mine Y. Egg yolk antibodies for passive immunity. Annu Rev Food Sci Technol 2012; 3: 163-182.
21. Mine Y, Kovacs-Nolan J. Chicken egg yolk antibodies as therapeutics in enteric infectious disease: a review. J Med Food 2002; 5: 159-169.
22. Müller S, Schubert A, Zajac J, Dyck T, Oelkrug C. IgY antibodies in human nutrition for disease prevention. Nutr J 2015; 14: 109.
23. Do LH, Vi TT, Le HT, Do TM, Do DK, Nguyen DD, et al. The inhibitory effect of anti-urease IgY on Helicobacter pylori infection in Swiss albino mice. Pharm Sci Asia 2021; 48: 255-268.
24. Ayala G, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014; 20: 1450-1469.
25. Malekshahi ZV, Gargari SL, Rasooli I, Ebrahimizadeh W. Treatment of Helicobacter pylori infection in mice with oral administration of egg yolk-driven anti-UreC immunoglobulin. Microb Pathog 2011; 51: 366-372.
26. Shin JH, Yang M, Nam SW, Kim JT, Myung NH, Bang WG, et al. Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection. Clin Diagn Lab Immun 2002; 9: 1061-1066.
27. Shin J-H, Roe I-H, Kim H-G. Production of anti-Helicobacter pylori urease-specific immunoglobulin in egg yolk using an antigenic epitope of H. pylori urease. J Med Microbiol 2004; 53: 31-34.
28. Hong KS, Ki MR, Ullah HMA, Lee EJ, Kim YD, Chung MJ, et al. Preventive effect of anti-VacA egg yolk immunoglobulin (IgY) on Helicobacter pylori-infected mice. Vaccine 2018; 36: 371-380.
| Files | ||
| Issue | Vol 17 No 3 (2025) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijm.v17i3.18823 | |
| Keywords | ||
| Immunoglobulin Y Therapeutic Helicobacter pylori Cell line C57BL Mice Gastrointestinal diseases | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Kamal Shahsavar S, Esmaeili Z, Ariannejad H, Nassiri M, Beheshti Namdar A, Jafarian AH, Sadeghi R, Dabbagh VR, Ghazvini K. Evaluation of the prevention, treatment and synergistic activity between Helicobacter pylori IgY antibodies and pantaprazole on AGS cell line and C57BL/6 Mice. Iran J Microbiol. 2025;17(3):404-410.
